AIMS: The aims of this study is to assess by an updated meta-analysis the clinical outcomes related to permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) at long-term (≥12 months) follow-up (LTF). METHODS AND RESULTS: A comprehensive literature research was performed on PubMed and EMBASE. The primary endpoint was all-cause death. Secondary endpoints were rehospitalization for heart failure, stroke, and myocardial infarction. A subgroup analysis was performed according to the Society of Thoracic Surgeon-Predicted Risk of Mortality (STS-PROM) score. This study is registered with PROSPERO (CRD42021243301). A total of 51 069 patients undergoing TAVI from 31 observational studies were included. The mean duration of follow-up was 22 months. At LTF, PPI post-TAVI was associated with a higher risk of all-cause death [risk ratio (RR) 1.18, 95% confidence interval (CI) 1.10-1.25; P < 0.001] and rehospitalization for heart failure (RR 1.32, 95% CI 1.13-1.52; P < 0.001). In contrast, the risks of stroke and myocardial infarction were not affected. Among the 20 studies that reported procedural risk, the association between PPI and all-cause death risk at LTF was statistically significant only in studies enrolling patients with high STS-PROM score (RR 1.25, 95% CI 1.12-1.40), although there was a similar tendency of the results in those at medium and low risk. CONCLUSION: Patients necessitating PPI after TAVI have a higher long-term risk of all-cause death and rehospitalization for heart failure as compared to those who do not receive PPI. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The aims of this study is to assess by an updated meta-analysis the clinical outcomes related to permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) at long-term (≥12 months) follow-up (LTF). METHODS AND RESULTS: A comprehensive literature research was performed on PubMed and EMBASE. The primary endpoint was all-cause death. Secondary endpoints were rehospitalization for heart failure, stroke, and myocardial infarction. A subgroup analysis was performed according to the Society of Thoracic Surgeon-Predicted Risk of Mortality (STS-PROM) score. This study is registered with PROSPERO (CRD42021243301). A total of 51 069 patients undergoing TAVI from 31 observational studies were included. The mean duration of follow-up was 22 months. At LTF, PPI post-TAVI was associated with a higher risk of all-cause death [risk ratio (RR) 1.18, 95% confidence interval (CI) 1.10-1.25; P < 0.001] and rehospitalization for heart failure (RR 1.32, 95% CI 1.13-1.52; P < 0.001). In contrast, the risks of stroke and myocardial infarction were not affected. Among the 20 studies that reported procedural risk, the association between PPI and all-cause death risk at LTF was statistically significant only in studies enrolling patients with high STS-PROM score (RR 1.25, 95% CI 1.12-1.40), although there was a similar tendency of the results in those at medium and low risk. CONCLUSION: Patients necessitating PPI after TAVI have a higher long-term risk of all-cause death and rehospitalization for heart failure as compared to those who do not receive PPI. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gilbert H L Tang; Syed Zaid; Iassen Michev; Hasan Ahmad; Ryan Kaple; Cenap Undemir; Martin Cohen; Steven L Lansman Journal: JACC Cardiovasc Interv Date: 2018-08-27 Impact factor: 11.195
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Arjun D Sharma; Carlos Rizo-Patron; Alfred P Hallstrom; Gearoid P O'Neill; Stephen Rothbart; James B Martins; Marc Roelke; Jonathan S Steinberg; H Leon Greene Journal: Heart Rhythm Date: 2005-08 Impact factor: 6.343
Authors: Alec Vahanian; Friedhelm Beyersdorf; Fabien Praz; Milan Milojevic; Stephan Baldus; Johann Bauersachs; Davide Capodanno; Lenard Conradi; Michele De Bonis; Ruggero De Paulis; Victoria Delgado; Nick Freemantle; Martine Gilard; Kristina H Haugaa; Anders Jeppsson; Peter Jüni; Luc Pierard; Bernard D Prendergast; J Rafael Sádaba; Christophe Tribouilloy; Wojtek Wojakowski Journal: Eur Heart J Date: 2022-02-12 Impact factor: 35.855
Authors: Thomas G Gleason; Michael J Reardon; Jeffrey J Popma; G Michael Deeb; Steven J Yakubov; Joon S Lee; Neal S Kleiman; Stan Chetcuti; James B Hermiller; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John V Conte; Mubashir Mumtaz; Jae K Oh; Jian Huang; David H Adams Journal: J Am Coll Cardiol Date: 2018-09-21 Impact factor: 24.094
Authors: Anthony D Pisaniello; Haytham B E Makki; Saleem Jahangeer; Matthew J Daniels; Ragheb Hasan; Douglas G W Fraser Journal: Circ Cardiovasc Interv Date: 2021-01-12 Impact factor: 6.546